| Development of a target cell-biologics-effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents X Jiang, X Chen, TJ Carpenter, J Wang, R Zhou, HM Davis, DL Heald, ... MAbs 10 (6), 876-889, 2018 | 42 | 2018 |
| Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model H Ma, H Wang, RJ Sové, J Wang, C Giragossian, AS Popel Journal for immunotherapy of cancer 8 (2), 2020 | 36 | 2020 |
| Tumor priming by SMO inhibition enhances antibody delivery and efficacy in a pancreatic ductal adenocarcinoma model J Wang, DKW Chan, A Sen, WW Ma, RM Straubinger Molecular cancer therapeutics 18 (11), 2074-2084, 2019 | 33 | 2019 |
| A quantitative systems pharmacology model of T cell engager applied to solid tumor H Ma, H Wang, RJ Sove, M Jafarnejad, CH Tsai, J Wang, C Giragossian, ... The AAPS Journal 22, 1-16, 2020 | 27 | 2020 |
| Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer MK Greene, T Chen, E Robinson, NL Straubinger, C Minx, DKW Chan, ... British Journal of Cancer 123 (10), 1502-1512, 2020 | 15 | 2020 |
| Quantitative systems pharmacology modeling of PBMC-Humanized mouse to facilitate preclinical Immuno-oncology drug development H Ma, M Pilvankar, J Wang, C Giragossian, AS Popel ACS Pharmacology & Translational Science 4 (1), 213-225, 2020 | 14 | 2020 |
| Overexpression and purification of recombinant atrial natriuretic peptide using hybrid fusion protein REF-ANP in Escherichia coli J Wang, W Chen, J Lu, S Lu Protein expression and purification 28 (1), 49-56, 2003 | 12 | 2003 |
| High level expression of human atrial natriuretic peptide in fusion form in E. coli system WJ Chen, J Wang, JZ Lu, SD Lu Zhongguo yi xue ke xue Yuan xue bao. Acta Academiae Medicinae Sinicae 23 (6 …, 2001 | 4 | 2001 |
| Using quantitative systems pharmacology modeling to optimize combination therapy of anti-PD-L1 checkpoint inhibitor and T cell engager S Anbari, H Wang, Y Zhang, J Wang, M Pilvankar, M Nickaeen, S Hansel, ... Frontiers in Pharmacology 14, 1163432, 2023 | 3 | 2023 |
| Analyze impact of tumor-associated kinetics on antibody delivery in solid tumors with a physiologically based pharmacokinetics/pharmacodynamics model J Wang, C Giragossian, S Hansel European Journal of Pharmaceutics and Biopharmaceutics 168, 110-121, 2021 | 2 | 2021 |
| Integrated PK/PD Modeling Relates Smoothened Inhibitor Biomarkers to The Heterogeneous Intratumor Disposition of Cetuximab in Pancreatic Cancer Tumor Models J Wang, T Chen, DM Ruszaj, DE Mager, RM Straubinger Journal of Pharmaceutical Sciences 113 (1), 72-84, 2024 | | 2024 |
